Last updated on November 2017

AMP, Antibody Mediated Prevention: A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men (HVTN 704)


Brief description of study

AMP, Antibody Mediated Prevention: A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men (HVTN 704)

Detailed Study Description

Researchers at Brigham and Women's Hospital are looking for men (MSM) and transgender individuals (FTM & MTF) who have sex with men to participate in an upcoming HIV vaccine trial testing a new idea for prevention, antibody mediated prevention, or AMP.

AMP is a multi-site, international phase 2b clinical trials being conducted in partnership by the HIV Vaccine Trials Network and the HIV Prevention Trials Network to determine the safety and effectiveness of VRC01, an antibody found to be particularly effective at neutralizing HIV. Participants will be randomized (assigned by chance ) to a control group, which receives a placebo, or the intervention group, which receives the study drug. The drug will be administered by intravenous (IV) infusion.

Clinical Study Identifier: TX14624

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Research Study Staff

Brigham and Women's Hospital
Boston, MA USA
  Connect »